For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Acquired in-process research and development | 0 | |||
| Research and development | 349,000 | |||
| General and administrative | 5,693,000 | |||
| Gain on sale of dismutase mimetics assets | 3,500,000 | |||
| Write-off of acquired intangible asset | 0 | |||
| Write-off of goodwill | 0 | |||
| Gain on litigation settlement | 0 | |||
| Loss from operations | -2,542,000 | |||
| Interest income | 248,000 | |||
| Gain on extinguishment of debt | 151,049,000 | |||
| Change in fair value of warrant liability | -294,000 | |||
| Foreign currency loss | 0 | |||
| Income (loss) before income tax benefit | 149,049,000 | |||
| Income tax benefit | 0 | |||
| Net income (loss) | 149,049,000 | |||
| Basic EPS | 0.64 | |||
| Diluted EPS | 0.64 | |||
| Basic Average Shares | 98,503,430 | |||
| Diluted Average Shares | 98,503,430 | |||
Galera Therapeutics, Inc. (GRTX)
Galera Therapeutics, Inc. (GRTX)